We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for sacituzumab govitecan (Adjutor Healthcare Pty Ltd)
Active ingredients
sacituzumab govitecan
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies
Therapeutic area
Oncology